Why Is the New York Times Laundering the Reputation of a Sleazy AI Startup That’s Selling GLP-1s via a Dishonest Dumpster Fire of Fake Doctors, Phony Before-and-After Pictures, and Other Glaring Red Flags?
TL;DR
Futurism accuses the New York Times of giving uncritical positive coverage to AI startup Medvi, which sells GLP-1 weight-loss drugs through an automated prescription system.
Key Points
- Medvi allegedly uses fake doctor profiles, manipulated before-and-after photos, and deceptive marketing practices.
- Critics label the model bluntly as an 'automated GLP-1 prescription mill' lacking genuine medical oversight.
- The NYT piece reportedly ignored these red flags entirely, framing the startup as an innovative healthcare solution.
Nauti's Take
The real scandal here is not the startup – prescription mills have always existed. The problem is the NYT apparently doing zero due diligence before platforming Medvi.
When 'AI in healthcare' passes as a quality signal without anyone asking whether real doctors are actually involved, journalism has failed its basic function. Futurism's callout is a reminder of how desperately the AI hype cycle needs adversarial reporting – especially in domains where patient safety is on the line.
Context
AI-powered telehealth platforms dispensing prescription drugs operate in a regulatory grey zone where genuine physician review is often fiction. When legacy journalism like the NYT profiles such providers without critical scrutiny, it normalises dubious practices and erodes public trust in legitimate medicine. The GLP-1 boom makes this urgent: millions seeking weight-loss drugs are prime targets for exactly these kinds of operations.
Video
Sources